Thank you, Jack, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans and timelines as well as timelines for data release and partnership opportunities. These statements are subject to risks and uncertainties and we refer you to our SEC filings for more details on these risks. Joining me today are Dr. Garo Armen, Chairman and Chief Executive Officer; and Christine Klaskin, Vice President of Finance. Our Chief Medical Officer, Dr. Steven O'Day, will be joining us for Q&A. Now, I'd like to turn the call over to Garo to highlight our progress and speak to our outlook for the remainder of the year. Garo?

Thank you, Nico. Once again, good morning and thank you for joining us yesterday for our third quarter update and numbers discussion. It is an exciting time for Agenus and we believe also for the field of immuno-oncology. The Society for Immunotherapy of Cancer otherwise known as SITC Conference starts today in Boston, our home turf, during which we expect to highlight the significant unrealized potential for a new generation of I-O regimens, I-O being immuno-oncology, that potentially would transform the way we treat cancer. We anticipate that one of our most promising clinical assets balstilimab, a novel adaptive innate immune activator in addition to being a CTLA-4 binder can provide important future therapeutic options for patients with tumors that are particularly resistant to current therapies, including very importantly immunotherapies. On today's call, we will provide an update on balstilimab development programs, including our participation at SITC as well as recent initiation of two Phase 2 ACTIVATE trials, one in advanced colorectal cancer and two in melanoma, to be followed by a trial in pancreatic cancer before the end of the year. It's important to point out that all of these trials are randomized trials. We will also highlight progress on several of our earlier stage clinical programs, including our ILT2 antagonist, AGEN1571 and our CD137 agonist AGEN2373 and provide a financial update. Let me start with SITC. We will be sharing expanded clinical data from our Phase 1 study of balstilimab across multiple tumor-specific cohorts of heavily pretreated patients, where we presented the data in colorectal cancer several months ago, at ESMO GI in Barcelona. The experts at that time scrutinized the heavily pretreated nature of these patients and it was the consensus that the data presented was unique in that it was both in heavily pretreated patients as well as in cold colorectal tumors. Both of them, by the way, increase the odds of non-responsiveness, and the fact that we have seen responses in that population is the impetus for enthusiasm by experts for balstilimab. So now these data will be presented at an oral plenary session on an expanded patient population whereas we presented the data in colorectal patients at ESMO, the SITC presentation will encompass expanded cancers. And it will be on November 12 at 10:50 AM. The presentation is by Dr. Bree Wilky, the Director of Sarcoma Medical Oncology and Deputy Associate Director for Clinical Research University at the University of Colorado, and it is a plenary session. Agenus will also present translational data from the Phase 1 study. And by the way, again, this is a very large Phase 1 study, not a common Phase 1 study, having already enrolled over 250 patients, although the data presented will be about half of that number, given the fact that we are presenting data on patients that have had at least one scan to collect data from. And so, Agenus will present translational data from the Phase 1 study and preclinical studies highlighting the mechanisms of underpinning what balstilimab differentiated enhanced anti-tumor immunity as well as new preclinical data demonstrating superior activity than first-generation CTLA-4 agents across multiple cold and totally immunogenic tumor models. And as we have communicated, later on November 12, Agenus will host The Road Taken conference, which is an Agenus sponsored conference. This R&D event features presentations from key opinion leaders at the forefront of immunotherapy development including Dr. Michael Adkins, Dr. Alexander Eggermont, Dr. Bree Wilky, the presenter of the plenary session that morning and Dr. Larry Norton, as well as multiple presentations from our own leadership team. The agenda will center under current and future states of I-O treatments as well as the unprecedented data generator to date in the botensilimab program. The event will take place from 2:00 PM to 5:00 PM Eastern Standard on November 12 at the offices of Ropes & Gray in Boston. While in-person attendance is now closed due to space restrictions, institutional investors, analysts, and members of the medical community are invited to attend the live webcast of the event, which can be accessed on the investor section of our Agenus website, although I might indicate that there are limits to the participation of that as well. Agenus made several important clinical advancements to our botensilimab program in the third quarter. Building upon the robust responses of the drug in our Phase 1 trial, we have already initiated two randomized worldwide Phase 2 ACTIVATE trials in advanced MSS, that is Microsatellite Stable, or it can also be described as non-MSI-CRC patients as well as melanoma. The ACTIVATE-Colorectal trial will evaluate botensilimab monotherapy and in combination with balstilimab our PD-1 antibody. It is randomized to current standards of care in patients that have received at least one prior chemotherapy regimen. So again, these are pretreated patients that have failed the standard of care in the prior setting. The ACTIVATE-Melanoma trial will evaluate botensilimab monotherapy in patients with refractory to either PD-1 or combined CTLA-4 PD-1 therapy. And this is also a very important trial design because it may achieve the approval of botensilimab as monotherapy in a continuing approval trial. And of course, there are benefits to going after the botensilimab monotherapy indication. The primary endpoint of both studies will be overall response rates, with durational response, progression-free survival, and overall survival as primary and secondary endpoints. This is also important because all of these endpoints are considered the gold standard in clinical trial conduct. The Agenus expects to launch, as I said earlier, a third Phase 2 trial in advanced pancreatic cancer by year-end. This too will be a randomized trial and it will look at botensilimab in combination with chemotherapy versus chemotherapy alone. Beyond these trials, Agenus continues to enroll patients in its Phase 1 botensilimab study to evaluate expansion cohorts in additional indications. These expansion cohorts will evaluate efficacy signals as well as support those optimization and contribution of components for the PD-1 combinations. These larger and richer data sets that will be obtained from the expansion of our Phase 1 trials can be used to accelerate our Phase 2 programs as well as support additional indications for development. And while we have not made a disclosure on what additional indications we will be going after, we have a clear vision of what they are, and they include some very difficult cancers as well as some very large cancer opportunities, beyond the communications that we've mentioned for the subject of clinical trials this year. Complementing the progress we've made on botensilimab this quarter, we're advancing additional clinical programs developed from our antibody engineering vision platform. This is very important also to mention that every product other than our first-generation CTLA-4 and our PD-1 has been specifically engineered with attributes in mind, and of course, botensilimab is a clear example of that attribute, which has been designed into the molecule, which has been proven to be validated in preclinical models. And now, we're seeing that to be validated in clinical trials. So getting back to our other agents, we hosted our very first patient in our Phase 1 study evaluating AGEN1571. This is an ILT2 antagonist antibody and we're doing the Phase 1 trial, first as monotherapy and then it will be in combination with botensilimab and balstilimab in patients with advanced solid tumors. We continued enrollment of our combination study evaluating AGEN2373, which is our CD137 agonist. This is with botensilimab in melanoma patients who are relapsed or refractory to PD-1 therapy. We anticipate enrollment should be completed in the first half of 2023 or sooner. Agenus has a robust track record of value creation through strategic partnerships and this quarter multiple partner assets advanced into new Phase 2 studies. For example, BMS launched a Phase I/II study of BMS-986442, which is our old TIGIT bispecific licensed to them, which was discovered by us and is also known as AGEN1777. BMS-986442 is being evaluated in combination with nivolumab, their own PD-1 and chemotherapy in patients with advanced solid tumors and non-small cell lung cancer. Second, Merck has initiated a randomized Phase II study evaluating MK-4830, a candidate ILT4 antagonist also discovered by Agenus, and this is in combination with pembrolizumab, Merck's own PD-1 and chemotherapy in ovarian cancer. Additional Phase 2 studies of MK-4830 are also ongoing in non-small cell lung cancer, small cell lung cancer, as well as esophageal cancer, MSI-high colorectal cancer, renal cell carcinoma, and melanoma. We are very encouraged by the fact that our ILT4 antagonist antibody has indications of activity in all of these very tumors. Lastly, Incyte initiated a randomized Phase 2 study evaluating LAG-3 and TIM-3 antibodies discovered by Agenus in combination with PD-1 in first-line squamous cell carcinoma of the head and neck. Additional Phase 2 studies of these programs are ongoing in melanoma, endometrial cancer, and urothelial carcinoma. Finally, our ability to recruit tough talent is critical to the development of our pipeline, near-term, more specifically botensilimab into a transformative treatment for patients indeed. To this end, we made some important recent additions to further bolster our clinical and regulatory leadership team. They include Dr. Todd Yancey, who was named Senior Global Clinical Development, Medical Affairs & Commercial Advisor. He comes with over 40 years of combined clinical and industry experience, most recently from BeiGene. We also hired Patricia Carlos as our Chief Regulatory, Quality and Safety Officer. Pattie has over 20 years of regulatory affairs experience, leading programs from investigational NDA to commercialization, as she was most recently at Arcus. With that, I will now turn the call over to Christine to cover our financial reporting.

Thank you, Garo. We ended our third quarter 2022 with a cash, cash equivalents and short-term investment balance of $218.2 million, compared to $238.3 million and $306.9 million on June 30, 2022, and December 31, 2021, respectively. Cash used in operations was $32.2 million for the quarter ended September 30, 2022, and $128 million for the nine months then ended. We recognized revenue of $22.8 million and incurred a net loss of $56.7 million or $0.19 per share for the third quarter ended September 30, 2022. For the nine months ended September 30, 2022, we recognized revenue of $69.6 million and incurred a net loss of $156.6 million or $0.54 per share. Non-cash operating expenses for the third quarter and nine months ended September 30, 2022, were $22.2 million and $62.8 million, respectively. I'll now turn the call back to Garo.

Thank you very much, Christine. In closing, I just want to reiterate three things. One is the fact that we have an important pipeline of agents, a very important pipeline of agents that allows us to be able to assemble the right combinations at our own terms. And this is very important not only because these pipeline of agents have very unique attributes that allow us to expand our horizons beyond just a segment of cultures, like to earlier stage disease as well as hard tumors. So, it's a very exciting pipeline, and we're very heartened by some of the data that we will be disclosing in the first half of next year that highlights the important attributes of our pipeline. Now, secondly, I should also say that there are questions, for example, about our ability and our efforts to finance our pipeline because we have a robust pipeline and it takes resources to advance this pipeline. And let me make a couple of comments and some historical reflections on how we have done this in the past and how we will continue to do it. For example, if you look at the past ten years, we have funded our operations largely from two sources. One, the largest source cash received from partners and royalty financing transactions in combination partnership and royalty financing transactions have netted us over $900 million over these last ten years. In addition to that, we have also done equity offerings primarily through our ATMs. ATMs are an important instrument for us because they allow us to manage our cash balances quarter to quarter, year to year, to make sure that cash balances do not drop below a certain level based on our anticipated uses of cash, it is very important. And this flexibility has allowed us to be able to finance our needs until the next large infusion of cash, which typically is through anticipated partnerships. So with that, I think I will conclude my remarks and we will of course disclose much more data that hopefully will shed light into our excitement during our weekend activities, both at the SITC plenary session, SITC poster sessions, as well as at our Road Taken event on Saturday from 2 to 5. Thank you very much for your time, and I will be open to questions from the audience.

David Dye with SNBC. Your line is open.

Thanks for taking my question. And congrats on the progress, especially on the balstilimab update on SITC. So, first question just around the SITC update for balstilimab, and we saw at the SITC abstract earlier this morning that the cutoff is in April. So, I'm wondering if you can share any kind of color on the incremental updates we'll be expecting from the update at the SITC?

So, a couple of comments on this end and I will turn it over to Dr. O'Day to answer the rest of it. But as you know, we provided results from our colorectal cancer trial with botensilimab plus balstilimab at ESMO GI at the end of June. Now since then, we have additional patients from CRC that will be presented also at SITC. I cannot disclose exactly how many patients, but there'll be a meaningful addition to the denominator that was disclosed at ESMO GI at the end of June. In addition to that, we will be presenting several other indications with data that is mature and has been cleaned up. Both are very important requirements, so it has to be matured and cleaned up. And we are reserving, of course, additional patient data to be presented at major conferences in the very early part of next year as well. So Steven, would you like to add to that?

Yes. Good morning. Dr. Steven O'Day, the Chief Medical Officer at Agenus. I mean, Garo summarized it well. Obviously, the SITC abstract went in months ago with a cutoff of April. As you can imagine, this is a large Phase 1 trial that's rapidly accruing expansion cohorts, and we look forward to updating the data with the oral plenary session on Saturday, which will be a more mature update of data cut and expansion of these cohorts, so looking forward to sharing that this week.

That's really helpful. And then just want to follow up on the SITC abstract, we saw some data from the ovarian cancer, especially from the platinum-resistant ovarian cancer where we saw a 28% ORR. This to me seems to be quite impressive because historical response for PD-1 in platinum-resistant ovarian cancer is around 10%. And so, I'm just wondering, can you share with us your thoughts around potentially moving into the platinum-resistant ovarian cancer as another indication? Any thoughts around that would be helpful?

Sure. Other than the fact that we have to be careful about disclosing specifics before the actual plenary session, Steven, can you provide additional color on specifically ovarian cancer and the comment about 10% being the response rates for PD-1?

Yes. I think all of the subgroups of patients that we're expanding and getting data on are in very difficult to treat settings in which they are what we call cold tumors or already exposed to PD-1-based therapies and refractory. So certainly, a refractory platinum-resistant exposed ovarian population has been a weak sort of immune opportunity in terms of PD-1 monotherapy, as you've indicated. So, we're obviously excited about this as well as other diseases that are showing this kind of promise with response rates that appear higher than substantially higher than what you would expect with PD-1 monotherapy. And we look forward, again, to updating this cohort and others on the plenary session on Saturday.

Got it. That's really helpful. And then just one last question on the 1571 the ILT2 antagonist program. Maybe I missed it earlier, Garo, when you mentioned the kind of incremental updates from that program. Can you share with us when we should be expecting to hear from you on the data front from that program?

So, let me ask Dhan, who is also here to give you a very brief rationale based on extensive pre-clinical data as well as the data from a similar family of compounds that we discovered and licensed to Merck, and that clinical data and perhaps you can draw some inferences then if Steven has anything else to add.

Yes. Thank you, Garo. So, AGEN1571, which is our ILT2 antagonist antibody designed to alleviate the suppressive myeloid suppressive function in the microenvironment in addition to enhancing the lymphoid activity as well. We discovered that patients that do not respond to PD-1 or CTLA-4 not only have enrichment of myeloid cells, but also these myeloid cells express high levels of ILT2. And as such, we develop an antibody to block ILT2 inhibitory function in the two microenvironments. You would have seen from our disclosures earlier this year that AGEN1571 demonstrates not only monotherapy potential but also best-in-class activity compared to competing ILT2 antibodies. More importantly, we show synergy with botensilimab in preclinical models highlighting the importance of combining AGEN1571 with other agents in their portfolio. With respect to other family members, you would have seen data from Merck on our ILT4 antagonist that we licensed to them, demonstrating compelling activity in patients that did not respond or progress on pembrolizumab, again consistent with the discoveries that we made that this family is important in extending therapy to patients that don't respond to conventional checkpoint therapy. This molecule is progressing, 1571 is progressing in the clinic quite rapidly. Let Steven provide you with an update on when you can expect data readouts.

Yes. As Garo said and as Dhan said, the myeloid compartment is becoming more and more important from an immuno-biologic point of view and our ILT4 that Merck has is obviously moving forward successfully in a Phase 2 program. We're particularly excited about ILT2 for the reasons Dhan described. It's in first-in-human studies which are going well. Obviously, we can't predict when data might be available, but certainly, the studies are accruing and moving forward, and we could have as early as the end of next year data to share with the world. But certainly, we will have to monitor the data and continue to progress these trials.

Chi Wei with Jefferies, you can go ahead.

Hi. This is Chi Wei at Jefferies for Kelly Shi. Congratulations on the balstilimab data. I have two quick questions. First, regarding the response rates disclosed in the SITC abstract, could you clarify how many responses are confirmed and unconfirmed for each tumor type? Additionally, since various doses of balstilimab were used in this Phase 1 trial, did you observe any dose-dependent responses from the Phase 1 data?

So, the first question about confirmed versus unconfirmed, we only present confirmed responses at conferences. We do not do. We have additional unconfirmed data that is suggestible, for example, very strong disease control rate over a long period of time, but we don't register those as responses. They may, in fact, in a number of situations, these trending responses have translated to actual responses upon further scans. But in terms of the dose variances, Steven, would you like to address the fact that early on we had used lower doses and in fact that lower doses have seen some responses as well. But most of the data that you'll be seeing at SITC is at the equivalent of one mg and two mg.

Yes. I mean, as Garo said, the data is rapidly evolving in terms of confirmed and unconfirmed responses. Unconfirmed responses in a rapidly evolving trial may just mean that they haven't had their subsequent follow-up scans. So, I would be mindful of that. And we will obviously update data on Saturday with our responses in terms of confirmed responses. In terms of doses, obviously, this trial is looking at a large number of doses initially, both monotherapy and combination. We are certainly concentrating in the combination expanded cohorts and with 1 and 2 milligrams every six weeks in combination with balstilimab. And we've certainly also centered on a dose range for botensilimab also as monotherapy. So, we're rapidly building databases with what we think are effective and safe doses, both for monotherapy and combinations. And I think the data speaks for itself in terms of the remarkable clinical activity in these very hard to treat cold or IO resistant solid tumors.

Matt Phipps with William Blair. Your line is open.

Hi, everyone. I appreciate you taking my question. I'm looking forward to the event this weekend. In the CRC trial, I noticed the recent posting and could you remind us what percentage of patients you anticipate will be free of liver metastases after chemotherapy? Also, I understand that liver metastases are typically more challenging to treat with immunotherapies. Is there anything in your pipeline that you believe could address this patient group?

Dr. O'Day. Other than the fact that I just want to highlight, we are seeing responses in both liver metastases and non-liver metastases, although the frequency of responses in non-liver metastases is higher. But further, also I'd like to draw your attention that treated liver metastases. In other words, tumors that were in the liver and ablated either with chemotherapy or other surgical needs, also respond well in our trial. But Steven, please.

Yes, Matt, it's a great question. Obviously, liver metastases are a dominant feature of colorectal cancer, but there's a significant number of patients that have either never had liver metastases because of the patterns of metastasis or have limited disease that is treated. And certainly, we've shown clinical benefit across all comers, including tumor reductions in active liver metastases, marked reductions in tumor markers like CEA, and prolonged stable disease. So, we think we have clinical benefit across metastatic colorectal cancer. Certainly, the active, the non-active liver metastases, meaning those that have never had liver metastases or had limited treated liver metastases, are an enriched population. That's going to be the focus of our Phase 2 trial as we further look at dose and contribution. But we have every intention of looking at the all comers. In terms of our pipeline, how do we address? Well number one clinicians both surgeons, radiation therapists, and medical oncologists can be much more active at treating liver metastases in conjunction with systemic therapies that are very active outside the liver. And this has been a limitation of the field. So that opens up considerably. And in terms of our pipeline, the myeloid compartment is a particular challenge to liver metastases, and in fact, myeloid cells defend the tumors very well. So, our ILT2 program, as Dhan just said, that's both a myeloid and a lymphoid checkpoint. We are particularly interested in combining that with our portfolio. And we do have plans in our Phase 1 ILT2 trial to add both balstilimab and botensilimab to our ILT2. So more to come, but we have every intention of going after difficult to treat cancers in both liver and non-active liver metastases with our portfolio.

Thanks, Dr. O'Day. One other question on that melanoma trial, can you give us any sense of kind of what it's designed to show any thresholds or bars, especially between the dosage arms? I mean, we've seen some data for Yervoy in a post-PD-1 setting. But I guess, what would you even expect in a post-PD-1 plus CTLA-4 setting? Just I don’t know what you can provide there, Dr. O'Day?

Matt, what disease are we talking about?

In the melanoma trial that you guys opened, the ACTIVATE.

Yes, that's a great question. We've talked extensively about cold tumors or PD-1 resistant tumors. Melanoma serves as a good example of a hot tumor where we’ll be exploring a PD-1 resistant setting, specifically in the second line for both PD-1 resistant and CTLA-4 naive patients, as well as in PD-1 and CTLA-4 resistance scenarios. We've previously reported responses in our monotherapy for both cohorts of patients, so we look forward to that. For what we expect, the advantage of a second line melanoma trial using monotherapy with botensilimab is that we have substantial historical data on response rates. Ipilimumab typically has a response rate between 10% and 15% in the second line of PD-1 resistance but CTLA-4 naive, providing us with a clear benchmark to demonstrate the differentiation of botensilimab in this setting. In cases of failure with ipi/nivo in the second line, you'd anticipate a 0% response rate for a CTLA-4 agent. Thus, the bar is quite low for differentiation, but as Garo mentioned earlier, we view this as a CTLA-4 blocker that also acts as a novel innate and adaptive activator through Fc-enhancement. Essentially, we're facilitating the engagement of these antigen-presenting cells with T-cells to create a more robust priming and memory response. We believe this will be highly effective in melanoma and hot tumors, as well as in cases with weak neo-antigens where a stronger priming response is crucial.

Mayank Mamtani with B. Riley Securities. Your line is open.

Good morning. Thanks for taking our questions and congrats on the progress. So Dr. O'Day, I'm digging into the SITC abstract here and also fortunate to compare it against the next generation CTLA-4 from one of your peers in the market. Can you talk to the importance of duration of response that you are seeing in your overall cohort? And the fact that you are seeing complete responses, including with monotherapy, could you just touch on why that's important? And then I have a couple of follow-ups.

Thank you, Mayank. It's a critical question. We're in the business of trying to cure patients with cancer. And CTLA-4 obviously I was part of the really the revolution with CTLA-4. Its primary sort of contribution in my mind is deep response, particularly evidence of CRs that are durable and that lead to curative therapy. And so, we are very excited that our molecule both single agent and in combination is demonstrating single agent activity. I think the field is suffering tremendously from the lack of single agent activity as we look at other targets like TIGIT and others. And so, I think IDOs, of course, were another example of that in melanoma that fell. So, we are excited to see single agent activity, but not just activity, but deep responses that are durable. They really do drive overall survival curves, and most importantly for patients, meaningful clinical responses. Obviously, when we combine an active novel CTLA-4 with PD-1, not only are you driving priming and memory, but you are preventing exhaustion, and our combination studies in cold tumors are particularly reassuring in that regard that we are continuing to see evolving deepening responses. So, it's critical to the field to demonstrate single agent activity that's meaningful and then use it as a combinational foundation.

Great. Thank you. And also would love to hear how you might be making the decision to pursue pancreatic cancer, but maybe not yet refractory lung cancer and CRC where you do have these two responses? And I'm just curious what the profile of these patients were, the two out of three response rate that we have. Did they have higher CPI exposure and if it was both CTLA-4 and for another PD-1? And then I have one last question.

Yes, Mayank. What diseases are you speaking of?

You mentioned that you are progressing with pancreatic cancer, but we don’t see that information in this abstract. What we do see is related to lung cancer, specifically refractory lung cancer.

So, I think to Garo's earlier points, we are framing and very focused on three very important foundational experiments with our Phase 2 programs. One is obviously single agent activity in melanoma with our reference second line that will be differentiating and powerful. We are seeing obviously tremendous response and durability in colorectal, and we have a Phase 2 program. Pancreas, we haven't shared all of our data yet in the expanded Phase 1, but we have preclinical models showing a very powerful chemo-botensilimab data, and we have preliminary data in the clinic that is also supportive. So, that Phase 2 trial will be looking at botensilimab in a randomized Phase 2 trial with chemotherapy, so three separate experiments. But having said that, our development program is very thoughtful as going much deeper than those three programs, and so, you will see more data as we go forward in the next year and develop these plans and we will certainly reveal those. But we clearly have a lot of opportunity in big markets as the data is showing us. So, more to come on further development plans, but we do anticipate starting these trials this year and being very focused.

And my final question was just to remind us what the comparator arm is in the ACTIVATE-Colorectal Phase 2 study? And any thoughts on how that may compare against there's a Phase 3 LAG-3 PD-1 combination study also running in MSS colorectal. So I'm just curious if there are any design differences to be aware of?

I won't comment on the differences between trials. Our trial is focused on the second and third-line setting, specifically for patients who have not responded to chemotherapy and antibodies. It will include a standard of care arm, which in this case is Lonsurf as the typical treatment option for second or third-line therapy.

We do have a follow-up question from Chi Wei with Jefferies. Your line is open.

Just one additional question. Since you have seen a strong response in the NSCLC patients, could you comment on how many lung cancer patients have enrolled so far besides these three that you have disclosed?

We're not commenting on any specific numbers of patients until the actual presentation.

I would now like to turn the call back over to our presenters for closing comments.

Thank you very much everybody. Thanks again for joining us. We look forward to providing you with some more information in a few days. And please feel free to participate in our webcast. As I said earlier, in-person attendance is closed at this time because of space constraints and the number of inquiries we've had. And we look forward to our future interactions. Thanks again.

This concludes today's conference. We thank you for your participation. You may now disconnect.